Scholarlink

<p>In this 12-week trial, 136 participants with moderately dyslipidemia were randomly assigned to receive <i>Lactiplantibacillus plantarum</i> (LP) or placebo. In the intention-to-treat analysis, the group-by-time interaction did not reach statistical significance. However, in per-protocol set (adherence ≥85% and no antibiotic use), LP supplementation reduced low-density lipoprotein cholesterol (LDL-C) (−0.118 mmol/L) and total cholesterol (TC) (−0.163 mmol/L), compared with the placebo (both <i>P</i><sub>group×time</sub> &lt; 0.05). Post-intervention group differences were identified in gut microbial genera and species, correlated with changes in bile acids, which in turn were jointly related to lipid reduction. Microbiota-based machine learning models well-predicted the lipid reductions. Subjects with lower genetic risk scores experienced large decreases in LDL-C (Mean ± SD: −0.749 ± 0.632 mmol/L) and TC (−1.306 ± 0.436 mmol/L) (both <i>P</i><sub>trend</sub> and <i>P</i><sub>interaction</sub> &lt; 0.001). Our data supported the beneficial effects of LP in patients with moderate dyslipidemia involving gut microbiota and host genetics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Effects of Lactiplantibacillus plantarum on moderate dyslipidemia before medication involving gut microbiota and host genetics

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月9日

查看全文
  • Guoqing Ma,
  • Yunfeng Li,
  • Chen He,
  • Junqi Li,
  • Jiawen Xie,
  • Maab Mohammed Alballa,
  • Kun Xu,
  • Xinran Feng,
  • Juan He,
  • Kaizhen Jia,
  • Yifei He,
  • Wei Li,
  • Fangyao Chen,
  • Baibing Mi,
  • Jiaomei Yang,
  • Hang Yu,
  • Xia Liao,
  • Baoming Zhang,
  • Nan Yang,
  • Quanfeng Dong,
  • Qian Wang,
  • Xiaolei Ze,
  • Xin Liu

摘要

In this 12-week trial, 136 participants with moderately dyslipidemia were randomly assigned to receive Lactiplantibacillus plantarum (LP) or placebo. In the intention-to-treat analysis, the group-by-time interaction did not reach statistical significance. However, in per-protocol set (adherence ≥85% and no antibiotic use), LP supplementation reduced low-density lipoprotein cholesterol (LDL-C) (−0.118 mmol/L) and total cholesterol (TC) (−0.163 mmol/L), compared with the placebo (both Pgroup×time < 0.05). Post-intervention group differences were identified in gut microbial genera and species, correlated with changes in bile acids, which in turn were jointly related to lipid reduction. Microbiota-based machine learning models well-predicted the lipid reductions. Subjects with lower genetic risk scores experienced large decreases in LDL-C (Mean ± SD: −0.749 ± 0.632 mmol/L) and TC (−1.306 ± 0.436 mmol/L) (both Ptrend and Pinteraction < 0.001). Our data supported the beneficial effects of LP in patients with moderate dyslipidemia involving gut microbiota and host genetics.